Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 931Neoplasms 614Breast Neoplasms 613Colorectal Neoplasms 460Neoplasm Metastasis 399Ovarian Neoplasms 333Prostatic Neoplasms 316Melanoma 316Lung Neoplasms 295Multiple Myeloma 294Recurrence 282Squamous Cell Carcinoma of Head and Neck 248Stomach Neoplasms 233Pancreatic Neoplasms 232Leukemia, Myeloid, Acute 224Triple Negative Breast Neoplasms 194Endometrial Neoplasms 190Carcinoma, Renal Cell 183Lymphoma, Non-Hodgkin 179Carcinoma, Hepatocellular 178Small Cell Lung Carcinoma 166Leukemia, Lymphocytic, Chronic, B-Cell 158Advanced Solid Tumors 158Lymphoma, Follicular 150Lymphoma, Large B-Cell, Diffuse 141Urinary Bladder Neoplasms 140Lymphoma 138Advanced Solid Tumor 137Uterine Cervical Neoplasms 136Head and Neck Neoplasms 134

Interventions

cryoprecipitate coagulum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Afibrinogenemia × 1 year × Clear all
NCT06617897 2026-03-11

Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery

CSL Behring

Phase 3 Recruiting
90 enrolled

Afibrinogenemia, Blood Coagulation Disorders, Pseudomyxoma Peritonei

Data powered by HemOnc (CC BY 4.0) Colophon âš¡